Esketamine clinical trials: reply to Maju et al.-Reference-Cited by-同舟云学术

Esketamine clinical trials: reply to Maju et al.

Published:2020 Issue: Volume:29 Page:
ISSN:2045-7960
Container-title:Epidemiology and Psychiatric Sciences
language:en
Short-container-title:Epidemiol Psychiatr Sci

Author:

Gastaldon C.^ORCID,Papola D.,Ostuzzi G.^ORCID,Barbui C.^ORCID

Abstract

Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Epidemiology

Reference21 articles.

1. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

2. A Word to the Wise About Intranasal Esketamine

3. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3

4. National Institute for Health and Care Excellence (NICE) (2018) Depression in adults: recognition and management Clinical guideline [CG90]. Available at https://www.nice.org.uk/guidance/cg90 (Accessed July 2019).

5. Research on a ‘drug-centred’ approach to psychiatric drug treatment: assessing the impact of mental and behavioural alterations produced by psychiatric drugs

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced psychiatric disorders: A pharmacovigilance update;Therapies;2023-10

2. Virtual Reality as an Adjunct to Ketamine Infusion Therapy Increases Patient Satisfaction in the Management of Chronic Pain and Depression: A Retrospective Pilot Study;Journal of Behavioral and Brain Science;2023

3. Reply to the Comments by Doherty et al.;Psychotherapy and Psychosomatics;2020-10-22

4. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System;Psychotherapy and Psychosomatics;2020-08-27